Lorbrena FDA Approval History
Last updated by Judith Stewart, BPharm on March 10, 2021.
Lorbrena (lorlatinib) is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) positive as detected by an FDA-approved test.
Development Timeline for Lorbrena
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.